oprelvekin [IL-11] (Neumega)

Introduction

Tradename: Neumega.

Indications

• prevention of thrombocytopenia in cancer patients
• reduction in need for platelet transfusion following myelosuppressive chemotherapy

Dosage

• 50 ug/kg/day SC, 75 ug/kg/day SC in pediatric patients Injectable: 5 mg preservative-free vials

Pharmacokinetics

Elimination: 1st order. 1/2 life 7 hours

Adverse effects

• water retention & edema
• nausea/vomiting
• fever

More general terms

• biological response modifier
• interleukin-11